Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment

被引:0
作者
S J Bull
P Huezo-Diaz
E B Binder
J F Cubells
G Ranjith
C Maddock
C Miyazaki
N Alexander
M Hotopf
A J Cleare
S Norris
E Cassidy
K J Aitchison
A H Miller
C M Pariante
机构
[1] King's College London,Department of Psychiatry and Behavioral Sciences
[2] Section and Laboratory of Stress,Division of Psychological Medicine and Psychiatry
[3] Psychiatry and Immunology,Division of Psychological Medicine and Psychiatry
[4] Institute of Psychiatry,Department of Hepatology
[5] MRC SGDP Centre,Department of Psychiatry
[6] Institute of Psychiatry,undefined
[7] King's College London,undefined
[8] Emory University School of Medicine,undefined
[9] Institute of Psychiatry,undefined
[10] King's College London,undefined
[11] Weston Education Centre,undefined
[12] Section of Neurobiology of Mood Disorders,undefined
[13] Institute of Psychiatry,undefined
[14] King's College London,undefined
[15] St James's Hospital,undefined
[16] Cork University Hospital,undefined
来源
Molecular Psychiatry | 2009年 / 14卷
关键词
interleukin-6; serotonin transporter; depressive symptoms; fatigue; cytokine; immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
Depression and fatigue are frequent side effects of interferon-α (IFN-α) treatment, and there is compelling evidence that the inflammatory response system (including interleukin-6, IL-6) and the serotonergic system is important in the pathophysiology of such symptoms. Functional polymorphisms in the promoter region of the IL-6 gene (rs1800795) and serotonin transporter gene (5-HTTLPR) have been identified as regulating these systems. The present study aimed to determine if these polymorphisms were associated with the development of depression and fatigue during IFN-α and ribavirin treatment. Ninety-eight Caucasian patients receiving pegylated IFN-α and ribavirin treatment for chronic hepatitis C virus at King's College Hospital, London, and Emory University Hospital, Atlanta, participated in this prospective cohort study. Symptoms of depression and fatigue were measured before treatment and at weeks 4, 8, 12 and 24 during treatment. The ‘low IL-6’ synthesizing genotype (CC) was associated with significantly fewer symptoms of depression (effect size=0.7 at week 24; F=9.4, d.f.=436, P=0.002). The ‘high transcription’ serotonin transporter (5-HTT) genotype (LL) was also associated with significantly fewer symptoms of depression, but with a much smaller effect (effect size=0.2 at week 24; F=4.5, d.f.=436, P=0.03). Neither polymorphisms were associated with symptoms of fatigue (IL-6: F=1.2, d.f.=430, P=0.2; 5-HTT: F=0.5, d.f.=430, P=0.5). The smaller effects of the 5-HTT polymorphism on depression may be explained by an interaction between the genes (F=5.0, d.f.=434, P=0.02): the ‘protective’ effect of the 5-HTTLPR polymorphism was evident only in the presence of the ‘low IL-6’ genotype (F=5.4, d.f.=64, P=0.02), not in the presence of the ‘high IL-6’ genotype (F=2.2, d.f.=369, P=0.1). The association between the IL-6 polymorphism and reduced risk of depressive symptoms confirms the role of the inflammatory response system in the pathophysiology of IFN-α-induced depression; in contrast, the effect of the 5-HTT gene was small and perhaps dependent on the status of the inflammatory response.
引用
收藏
页码:1095 / 1104
页数:9
相关论文
共 320 条
  • [1] Manns MP(2001)Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958-965
  • [2] McHutchison JG(2005)Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response Mol Psychiatry 10 332-333
  • [3] Gordon SC(2005)Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C Brain Behav Immun 19 23-27
  • [4] Rustgi VK(2005)The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin Brain Behav Immun 19 271-272
  • [5] Shiffman M(2007)Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression? Chemotherapy 53 292-299
  • [6] Reindollar R(2005)Depressive symptoms and viral clearance: in response Brain Behav Immun 19 273-274
  • [7] Maddock C(1998)Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons Cancer Res 58 2489-2499
  • [8] Landau S(2000)C5b-9 and interleukin-6 in chronic hepatitis C. Surrogate markers predicting short-term response to interferon alpha-2b Scand J Gastroenterol 35 1092-1096
  • [9] Barry K(2003)Differential induction of serum interleukin-6 and -12 by interferon-alpha and -beta administration in chronic hepatitis C patients Hepatol Res 27 101-108
  • [10] Maulayah P(2001)Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 15 7-24